Mammoth Biosciences

Improving lives by reading and writing the code of life.

[Mammoth Biosciences @mammothbiosci]

We will be at #ASGCT25! Join us (in person or virtually) to hear about our latest results with NanoCas, the first efficient ultracompact extrahepatic gene editor. Despite its small size, NanoCas achieves efficient editing of muscle tissues in NHPs, a #CRISPR breakthrough.

[Mammoth Biosciences @mammothbiosci]

📢 In case you missed it, our latest study is now live!

#NanoCas, an ultracompact nuclease, enables efficient muscle editing in NHPs using a single AAV - advancing gene editing for hard-to-target tissues.

📄Read here: https://t.co/KrWKbTcgE5

#CRISPR #GeneEditing #Biotech

[Mammoth Biosciences @mammothbiosci]

🔬Our latest #NanoCas research is making waves!

Thrilled to see @GENbio coverage on #NanoCas!🎉 Our ultracompact nuclease enables single AAV delivery and efficient muscle editing in NHPs. A big thanks to @julemieux1 and @GENbio!

https://t.co/Rn0vkyfthP

#GeneEditing #Biotech

[Mammoth Biosciences @mammothbiosci]

🧬CRISPR proteins shrink, but its potential expands!

#NanoCas, featured in @ScienceMagazine, edits NHP muscle via single-AAV delivery – unlocking therapies for hard-to-target diseases. Huge thanks to @jcouzin for covering our research!

https://t.co/MEiERw9WqA

#CRISPR #Biotech

[Lucas Harrington @CRISPR_LuCas]

📢Excited to introduce NanoCas -our new mini CRISPR system that can reach tissues previously out of reach!

By shrinking CRISPR to 1/3 its normal size, we can now edit genes in muscle, heart & brain that were difficult to access before. Summary & link to paper:

[Mammoth Biosciences @mammothbiosci]

We are proud to announce #NanoCas, our ultracompact #CRISPR system, overcomes gene editing limits, enabling efficient muscle editing in NHPs using a single AAV vector.

💡Curious to learn more? Read more here: https://t.co/8t6RNGYRkG

#GeneEditing #Biotech #PrecisionMedicine

[Mammoth Biosciences @mammothbiosci]

We Won! Thank you everyone for your support, so proud of our work with #CRISPR, and thank you @CALifeSciences

[Mammoth Biosciences @mammothbiosci]

Last day to vote for Mammoth (Emerging Innovation): https://t.co/sFoYFipyQ5!

[Mammoth Biosciences @mammothbiosci]

We are 1/2 through - have you voted?

- Vote for Mammoth (Emerging Innovation):
https://t.co/sFoYFipyQ5
- Like this and repost!

Really proud of our ultracompact #CRISPR work to transform patients' lives and are grateful for the recognition that your vote and support brings! 😁

[Mammoth Biosciences @mammothbiosci]

So excited to be a finalist in the Emerging Innovation category of the @CALifeSciences #PantheonAwards. We're working to cure diseases through in vivo gene editing with our ultra compact #CRISPR systems, so please support us with your vote!
https://t.co/VXE2XJmDyz

[Mammoth Biosciences @mammothbiosci]

Thank you @WMIF2024, @MassGeneralNews @BankofAmerica, for hosting our Co-Founder & CTO @CRISPR_LuCas, on the "Deep Dive on Genetic Modalities for Rare Disease: Genetic Medicines Are Here" panel!

[Mammoth Biosciences @mammothbiosci]

Our Co-Founder @CRISPR_LuCas discusses #invivo and #CRISPR with @Erin_Harris1 from @_CellandGene
https://t.co/MU7A7dYtaQ

[Mammoth Biosciences @mammothbiosci]

Thanks @Bayer and @ask_bio for hosting at the AskBio Philly office! We made lasting memories and are excited to continue our partnership to develop cutting-edge gene editing therapies to improve the lives of patients suffering from conditions difficult to treat.
#CRISPR

[Alexa von Tobel, CFP @alexavontobel]

This week on @Inc For Starters, I spoke with Trevor Martin (@martintrevor_), CEO + Co-Founder of @mammothbiosci, the platform revolutionizing CRISPR-based biology products across therapeutics + diagnostics. Their ultimate goal: finding permanent cures for genetic diseases.

[Mammoth Biosciences @mammothbiosci]

Join us tomorrow morning at the @BioNJ_Org #BioPartnering Conference, where Mammoth's Chief Business Officer Phil Tinmouth will be taking part in the panel "BioPartnering: Keys to Success for Biotech and Pharma Partnerships."

[Genetic Engineering & Biotechnology News @GENbio]

ASGCT 2024: Mammoth Sizes Up Genome Editing Opportunities

Mammoth Biosciences CSO Lucas Harrington lays out his company's big plans in developing a range of therapeutic options using miniature Cas nucleases...Read more: https://t.co/n7RpZHOUYJ

[Mammoth Biosciences @mammothbiosci]

We're excited to be at #ASGCT2024 after the recent announcement of our collaboration with @Regeneron. Mammoth co-founder & CSO @CRISPR_LuCas will be sharing new preclinical data on our novel ultracompact CRISPR systems in an oral presentation today at 2:30 https://t.co/FyUuZkibxG

[Mammoth Biosciences @mammothbiosci]

Watch Mammoth co-founder and CSO @CRISPR_LuCas's oral presentation at #ASGCT2024, with new preclinical data on our platform's performance targeting the APOC3 gene, on Tuesday, May 7. Read the abstract: https://t.co/6H1dvoRkoq

[Regeneron @Regeneron]

We’re announcing a new collaboration with @mammothbiosci that pairs their ultracompact CRISPR editing systems with our innovative delivery technologies, expanding our targeted gene editing abilities across multiple tissue and cell types. Learn more: https://t.co/K7vFZyvMk3

[Mammoth Biosciences @mammothbiosci]

Join us in Baltimore for #ASGCT2024, where Mammoth will be presenting new preclinical data on our novel ultracompact CRISPR platform, as well as leading a symposium on advances in genome editing. We hope to see you there.